Stockreport

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics Ltd. - American Depositary Shares  (CMMB) 
PDF --FDA End-of-Phase 2 Meeting Scheduled in Fourth Quarter 2024 to Discuss the Design of a CM-101 Accelerated Approval Phase 3 Trial in Primary Sclerosing Cholangitis (PSC [Read more]